Table 3.

Summary of known DUB inhibitors that are targeted in cancer cells.

DUBs	DUBs Inhibitors	Therapeutic Targets	Functional Effects	References
USP8	9-Ethyloxyimino-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile	Non-small cell lung cancer	Downregulation of receptor tyrosine kinases including EGFR, ERBB2, ERBB3, and MET	[160]
UCHL1	LDN-57444	Lung cancer cell line	Inhibit proliferation	[161]
UCHL1, UCHL3	TCID	Multiple myeloma	Induce apoptosis	[162]
USP1	Pimozide	Leukemic cell lines	Promoted the degradation of ID1	[163]
USP1-UAF1	ML323	Non-small cell lung cancer and osteosarcoma cells	Induced DNA damage	[164]
USP1-UAF1	Pimozide and GW7647	Non–small cell lung cancer	Inhibit cell proliferation	[165]
USP2	ML346	Colorectal cancer nad mantle cell lymphoma	Accelerate cyclin D1 degradation, cell cycle arrest	[166]
USP2a/USP2b/USP5/USP8	AM146, RA-9 and RA-14	Breast, ovarian and cervical cancer cell lines	Downregulation cell-cycle promoter, and upregulation of tumor suppressor	[167]
USP5/IsoT, USP4	Vialinin A	Basophilic leukemia cells	Inhibit the release of TNFα	[168]
USP7	HBX 41,108	Colorectal carcinoma	Induced p53-dependent apoptosis	[156]
USP7/USP47	P5091 and Compound 1	Multiple myeloma	Induce apoptosis, inhibit tumor growth	[169,170]
USP9X/USP5/USP24	WP1130	Mantle cell lymphoma	Downregulation of antiapoptotic and upregulation of proapoptotic proteins, such as MCL-1 and p53	[171,172]
USP14/ UCHL5	AC17	Human lung cancer cells	Inhibit NFκB pathway and reactive p53	[173]
USP14/UCHL5	b-AP15 (WO2013058691)	Multiple myeloma/ colorectal carcinoma	Downregulation of CDC25C, CDC2, and cyclin B1/ overexpression of the anti-apoptotic mediator Bcl-2 and anti-tumor activity	[162,174]
USP14/UCHL5	VLX1570	Colon carcinoma cell	Inhibit proteasome DUB activity	[175]